Saturday, May 26, 2018

IMF's Lagarde Tells Turkey to Ensure Central Bank Independence

International Monetary Fund Managing Director Christine Lagarde urged the Turkish government to preserve the independence of its central bank after confusion sent the lira sliding.

Mixed signals about whether the central bank is free of political interference created a sense of uncertainty among investors, putting the currency under pressure, Lagarde said in an interview with Bloomberg Television in St. Petersburg.

#lazy-img-328052379:before{padding-top:66.68334167083543%;}

Christine Lagarde on May 25.

Photographer: Chris Ratcliffe/Bloomberg

"In terms of monetary policy, it’s always better for all political leaders to let the central bank governors do the job that they have to do, and to preserve and secure their independence," she said.

Turkey was engulfed by a currency crisis this month as President Recep Tayyip Erdogan said he would exert greater power over central banking if he won reelection. He subsequently pledged allegiance to global principles on monetary policy and the central bank boosted interest rates.

"Some of the comments made alerted the international community and particularly the investors to the fact that suddenly the central bank of Turkey could be under directions, instructions, or influence,” Lagarde said. “That has created a sense of uncertainty and a lack of confidence, which has found its way in the market.”

On Argentina, Lagarde said the IMF has been working actively with its officials to design measures to help stabilize the situation in its economy and restore confidence. She said the process was "progressing well."

"We are really moving ahead and we have committed to President Macri that we will do the best we can in order to move expeditiously and efficiently in order to change the perception about Argentina and the perception that people have about our role," Lagarde said. "So I am very, very focused on that relationship.”

Lagarde said the current outflows seen in emerging markets were expected, but that many markets are in much better shape today than at the time of the "taper tantrum" in 2013.

"We did say that with dollar strengthening and monetary policy tightening in the U.S. we would most likely see a flow back of capital from emerging markets," she said. "That’s obviously going to unsettle some the emerging markets that have not taken the necessary precautions or are weak in their fundamentals."

LISTEN TO ARTICLE 2:02 Share Share on Facebook Post to Twitter Send as an Email Print

Friday, May 25, 2018

Top 5 Casino Stocks To Buy For 2019

tags:SRPT,CRIS,TLF,ITHUF,NMFC,

Las Vegas Sands Corp (NYSE:LVS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Las Vegas Sands Corp operates fully integrated resorts with casino, hotel, entertainment. The company owns the Venetian Macao, Sands Macao, in Macau, the Marina Bay Sands resort in Singapore, the Venetian and Sands Bethlehem casinos in the United States. Las Vegas Sands Corp has a market cap of $58.76 billion; its shares were traded at around $74.33 with a P/E ratio of 20.99 and P/S ratio of 4.68. The dividend yield of Las Vegas Sands Corp stocks is 3.93%. Las Vegas Sands Corp had annual average EBITDA growth of 15.50% over the past ten years. GuruFocus rated Las Vegas Sands Corp the business predictability rank of 3-star.

For the last quarter Las Vegas Sands Corp reported a revenue of $3.4 billion, compared with the revenue of $3.1 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $12.9 billion, an increase of 12.9% from last year. For the last five years Las Vegas Sands Corp had an average revenue decline of 0.2% a year.

Top 5 Casino Stocks To Buy For 2019: Sarepta Therapeutics, Inc.(SRPT)

Advisors' Opinion:
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Sarepta Therapeutics (NASDAQ:SRPT)’s share price reached a new 52-week high and low on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares trading hands. The stock had previously closed at $92.22.

  • [By Keith Speights]

    But some stocks don't take nearly that long to double. Three stocks in particular�have doubled investors' money -- and more -- in just the last 12 months. Here's why Nektar Therapeutics (NASDAQ:NKTR), CRISPR Therapeutics (NASDAQ:CRSP), and Sarepta Therapeutics (NASDAQ:SRPT) became such huge winners -- and whether or not their impressive momentum can continue.

  • [By Max Byerly]

    Sarepta Therapeutics (NASDAQ:SRPT) had its target price increased by Morgan Stanley from $87.00 to $91.00 in a report issued on Friday. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.

  • [By Logan Wallace]

    Barclays upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from an equal weight rating to an overweight rating in a research report released on Friday morning, MarketBeat.com reports. They currently have $107.00 target price on the biotechnology company’s stock, up from their prior target price of $55.00.

Top 5 Casino Stocks To Buy For 2019: Curis, Inc.(CRIS)

Advisors' Opinion:
  • [By Logan Wallace]

    Curis, Inc. (NASDAQ:CRIS) shares fell 7.3% during trading on Monday . The company traded as low as $0.50 and last traded at $0.51. 1,663,387 shares were traded during trading, a decline of 12% from the average session volume of 1,888,812 shares. The stock had previously closed at $0.55.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Curis (CRIS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Casino Stocks To Buy For 2019: Tandy Leather Factory, Inc.(TLF)

Advisors' Opinion:
  • [By Shane Hupp]

    Tandy Leather Factory (NASDAQ: TLF) and Vera Bradley (NASDAQ:VRA) are both small-cap retail/wholesale companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Top 5 Casino Stocks To Buy For 2019: iAnthus Capital Holdings, Inc. (ITHUF)

Advisors' Opinion:
  • [By ]

    Much of the focus of cannabis investors has been centered on Canada and California. This makes sense given that they are the two largest recreational (or soon to be) cannabis markets in the world. However, one publicly traded company with US-centric cannabis operations has taken a different approach. iAnthus Capital is listed in Canada on the CSE (OTCQB:ITHUF), but is headquartered in New York and incorporated in Delaware. Unlike other Canadian-listed cannabis companies, most of which are aiming to get in on the highly competitive green-rush in California and Canada, iAnthus has set its sights on becoming the dominant player on the U.S. East Coast.

  • [By Javier Hasse]

    Licensed cannabis production facilities owner and operator iAnthus Capital Holdings Inc (OTC: ITHUF) announced a $50 million investment from Gotham Green Partners. Management believes this is the largest investment to date by a single investor in a publicly traded U.S. cannabis operating company. iAnthus plans to allocate the proceeds of this financing to repay a $20 million one-year note and accrued interest to VCP Bridge LLC; continue to build out cultivation facilities and dispensaries in the New York and Florida markets; and, potentially, to expand activities. The remaining expenditures for completing iAnthus’ Massachusetts and Vermont operations will be funded with current cash on hand, management assured.

  • [By Spencer Israel]

    The charts below are courtesy of VantagePoint, a platform that uses Artificial Intelligence and machine learning to forecast future price movements 1-3 days in advance with up to 86 percent accuracy. The blue line represents a predictive moving average that shows what’s going to happen three days in advance, and the black line is a simple 10-day moving average. A crossover of the blue line over the black line indicates a bullish signal from the software, and vice versa for a bearish signal.

    iAthus Capital Holdings, Inc. (OTC: ITHUF)

    Up 94 percent YTD

Top 5 Casino Stocks To Buy For 2019: New Mountain Finance Corporation(NMFC)

Advisors' Opinion:
  • [By Shane Hupp]

    These are some of the news headlines that may have effected Accern Sentiment’s scoring:

    Get New Mountain Finance alerts: New Mountain Finance (NMFC) Expected to Post Quarterly Sales of $50.86 Million (americanbankingnews.com) Zacks: Analysts Anticipate New Mountain Finance (NMFC) Will Post Earnings of $0.34 Per Share (americanbankingnews.com) New Mountain Finance (NMFC) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com) Is this stock is more Volatile? New Mountain Finance Corporation (NMFC) (stockquote.review) New Mountain Finance Corporation (NMFC): Stock Have a Latest Story: (mosttradedstocks.com)

    A number of equities analysts have recently weighed in on NMFC shares. Zacks Investment Research raised shares of New Mountain Finance from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Wednesday, March 21st. TheStreet downgraded shares of New Mountain Finance from a “b” rating to a “c+” rating in a research note on Wednesday, April 11th. ValuEngine downgraded shares of New Mountain Finance from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. Finally, Keefe, Bruyette & Woods set a $15.00 price target on shares of New Mountain Finance and gave the stock a “hold” rating in a research note on Thursday, March 1st. One investment analyst has rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $15.00.

Thursday, May 24, 2018

Top Growth Stocks To Invest In Right Now

tags:ISRG,MED,TBI,BWLD,JWN,

If you’ve invested in municipal bonds lately, you may be coming down with a serious case of buyer’s remorse.

But you shouldn’t, as I’ll explain in a moment. In fact, now is the perfect time to double down and buy more of these high-yielding, ultra-stable investments.

First, let’s look at why “munis” have fallen off a cliff, setting up an excellent buying opportunity for you and me.

“Off a cliff” is no exaggeration. Take a look at what’s happened to the five biggest muni-bond ETFs in the past month:

Muni Bonds Tank

When investments as stable as these put on a drop like that, you’d expect, say, a looming global financial crisis.

You could argue that Trump might bring us precisely that, but this sentiment runs counter to the jump in financial stocks—and the strength of stocks broadly—we’ve seen in the past few weeks, as well as the investment banks’ forecasts for rising GDP growth and inflation.

Top Growth Stocks To Invest In Right Now: Intuitive Surgical Inc.(ISRG)

Advisors' Opinion:
  • [By Brian Feroldi]

    TransEnterix (NYSEMKT:TRXC) recently surprised investors on the upside when it reported its first-quarter results. The company's�Senhance�surgical system is off to a fast start right out of the gate, and it has attracted a lot of positive attention from the medical community. This just goes to show how much demand is out there for an�alternative to Intuitive Surgical's (NASDAQ: ISRG)�dominant da Vinci platform.�

  • [By Garrett Baldwin]

    Earnings season is now in full swing, with today's key reports from�International Business Machines Corp. (NYSE: IBM), Johnson & Johnson (NYSE: JNJ), and Intuitive Surgical Inc.�(Nasdaq: ISRG). Thanks to tax cuts, expectations are high. Analysts expect profit growth to top 18%, which would be the biggest jump in seven years. But there are a few bearish trends that are still lurking in the market. And if you're serious about making money, you need to know how to harness them and target individual stocks for life-changing gains.�Money Morning�Quantitative Specialist Chris Johnson explains.

  • [By Lisa Levin] Gainers vTv Therapeutics Inc. (NASDAQ: VTVT) shares surged 115 percent to $2.56. Seadrill Limited (NYSE: SDRL) gained 77 percent to $0.3935. On Tuesday, a U.S. court approved the company's plan to exit Chapter 11 bankruptcy that includes raising around $1 billion in new debt and equity through a rights offering which will be led by its biggest shareholder. DropCar, Inc. (NASDAQ: DCAR) shares climbed 21.4 percent to $2.3301 after the company issued a preliminary Q1 update on its enterprise automotive business. The company disclosed that Q1 B2B automotive volumes rose 163 percent year-over-year. Teligent, Inc. (NASDAQ: TLGT) shares jumped 19.7 percent to $3.615 following the FDA approval of Clobetasol Propionate Cream USP, 0.05%. IZEA, Inc. (NASDAQ: IZEA) surged 19.1 percent to $2.62. IZEA posted a Q4 net loss of $743,000 on sales of $6.8 million. SunPower Corporation (NASDAQ: SPWR) shares gained 15.2 percent to $9.6180. SunPower announced plans to acquire SolarWorld Americas. LexinFintech Holdings Ltd. (NASDAQ: LX) climbed 10.2 percent to $15.20. CounterPath Corporation (NASDAQ: CPAH) shares rose 8.8 percent to $3.0033. Semiconductor Manufacturing International Corporation (NYSE: SMI) gained 8.2 percent to $6.685 after falling 0.80 percent on Tuesday. Energy XXI Gulf Coast, Inc. (NASDAQ: EGC) shares climbed 7.2 percent to $5.93. Textron Inc. (NYSE: TXT) shares rose 6.7 percent to $63.96 after the company reported stronger-than-expected earnings for its first quarter. Sibanye Gold Limited (NYSE: SBGL) gained 6.5 percent to $3.59 after dropping 4.53 percent on Tuesday. Calithera Biosciences, Inc. (NASDAQ: CALA) rose 6.3 percent to $6.75 after the company disclosed that the FDA has granted Fast Track designation to CB-839 in combination with cabozantinib for treatment of patients with advanced renal cell carcinoma. CSX Corporation (NASDAQ: CSX) gained 6.1 percent to $60.01 after reporting upbeat quarterly earnings
  • [By Motley Fool Staff]

    In the healthcare world, one of those has to be the impressive quarterly report from Intuitive Surgical�(NASDAQ:ISRG). The company increased its revenue by 25%, and accelerated its sales of the da Vinci robotic surgical systems that made it famous. But it's not just the expensive hardware that is allowing it to prosper -- it's that every machine needs a steady supply of the disposable instruments and accessories used during its procedures. The Fools consider the recent numbers, the outlook, and the investment thesis for Intuitive Surgical stock. But in the, say, anti-healthcare space, cigarette slinger�Philip Morris International�(NYSE:PM) took a big hit as demand slackened in major foreign markets. Sales of its e-cig devices are also not growing the way management had hoped.

  • [By Motley Fool Staff]

    In this segment from�MarketFoolery, host Chris Hill and Motley Fool Asset Management's Bill Barker consider the case for healthcare innovator Intuitive Surgical�(NASDAQ:ISRG), which has been on a tear for the past few years. Its pricey robots are growing ever more common and popular with hospitals and doctors, and based on the reaction of the market, investors must expect its current sales growth pace to continue.

  • [By Motley Fool Staff]

    Right now, it's time for that yearly review of the ones he picked to honor the month, and also the briefly famous pregnant giraffe: five companies, and the first letters of their tickers spelled out A-P-R-I-L. They were Axon Enterprise�(NASDAQ:AAXN), Grupo Aeroportuario del Pacific�(NYSE:PAC), ResMed�(NYSE:RMD), Intuitive Surgical (NASDAQ:ISRG), and Live Nation�(NYSE:LYV).

Top Growth Stocks To Invest In Right Now: MEDIFAST INC(MED)

Advisors' Opinion:
  • [By Lisa Levin]

    Medifast, Inc. (NYSE: MED) shares were also up, gaining 22 percent to $121.06 after the company reported strong Q1 results and raised its FY18 guidance.

  • [By Max Byerly]

    McCormick & Company, Incorporated (NYSE: MKC) and Medifast (NYSE:MED) are both consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

  • [By Lisa Levin] Gainers Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares jumped 29.86 percent to close at $2.87 on Friday. Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares gained 28.87 percent to close at $8.75 after reporting upbeat Q1 earnings. Mexco Energy Corporation (NYSE: MXC) gained 27.02 percent to close at $5.4744. Carbon Black, Inc. (NASDAQ: CBLK) climbed 26 percent to close at $23.94. Carbon Black priced its IPO at $19 per share. Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) rose 25.64 percent to close at $42.44 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban. Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.19 percent to close at $8.50 after reporting Q2 results. California Resources Corporation (NYSE: CRC) shares gained 22.45 percent to close at $31.58 following upbeat Q1 earnings. Atomera Incorporated (NASDAQ: ATOM) gained 22.31 percent to close at $6.25 after reporting Q1 results. Medifast, Inc. (NYSE: MED) shares jumped 22.27 percent to close at $121.46 after the company reported strong Q1 results and raised its FY18 guidance. Jerash Holdings (US), Inc. (NASDAQ: JRSH) gained 20.86 percent to close at $8.46. Pandora Media, Inc. (NYSE: P) rose 19.83 percent to close at $6.89 after reporting strong quarterly results. Shake Shack Inc (NYSE: SHAK) rose 18.01 percent to close at $55.95 on Friday after the company reported upbeat results for its first quarter and raised its FY18 guidance. Super Micro Computer, Inc. (NASDAQ: SMCI) rose 17.73 percent to close at $21.25 after reporting strong preliminary results for the third quarter. Schmitt Industries, Inc. (NASDAQ: SMIT) rose 17.41 percent to close at $2.36. Titan International, Inc. (NYSE: TWI) shares gained 16.78 percent to close at $12.25 following Q1 earnings. Integer Holdings Corporation (NYSE: ITGR) shares rose 14.23 percent to close at $63.40 following Q1 result
  • [By Lisa Levin] Gainers Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares rose 35.8 percent to $3.00. Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares surged 32 percent to $8.94 after reporting upbeat Q1 earnings. Carbon Black, Inc. (NASDAQ: CBLK) gained 29.6 percent to $24.62. Carbon Black priced its IPO at $19 per share. California Resources Corporation (NYSE: CRC) shares rose 26.8 percent to $32.70 following upbeat Q1 earnings. Pandora Media, Inc. (NYSE: P) gained 25 percent to $7.185 after reporting strong quarterly results. Medifast, Inc. (NYSE: MED) shares climbed 23.7 percent to $122.87 after the company reported strong Q1 results and raised its FY18 guidance. Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.2 percent to $8.4999 after reporting Q2 results. Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) gained 22.2 percent to $41.27 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban. Shake Shack Inc (NYSE: SHAK) rose 22.2 percent to $57.955 after the company reported upbeat results for its first quarter and raised its FY18 guidance. Atomera Incorporated (NASDAQ: ATOM) jumped 19.7 percent to $6.12 after reporting Q1 results. Super Micro Computer, Inc. (NASDAQ: SMCI) rose 16.4 percent to $21.00 after reporting strong preliminary results for the third quarter. Titan International, Inc. (NYSE: TWI) shares rose 16.4 percent to $12.21 following Q1 earnings. Integer Holdings Corporation (NYSE: ITGR) shares gained 14.9 percent to $63.75 following Q1 results. Control4 Corporation (NASDAQ: CTRL) shares climbed 14.5 percent to $23.98 folloiwng strong Q1 results. B&G Foods, Inc. (NYSE: BGS) climbed 12.6 percent to $25.40 after reporting Q1 earnings. HMS Holdings Corp (NASDAQ: HMSY) shares gained 10 percent to $19.59 after reporting upbeat quarterly earnings. Viavi Solutions Inc. (NASDAQ: VIAV) rose 7 percent to $10.09 following Q3 r
  • [By Lisa Levin]

    Medifast, Inc. (NYSE: MED) shares were also up, gaining 25 percent to $124.60 after the company reported strong Q1 results and raised its FY18 guidance.

Top Growth Stocks To Invest In Right Now: TrueBlue Inc.(TBI)

Advisors' Opinion:
  • [By Logan Wallace]

    Trueblue (NYSE: TBI) is one of 23 public companies in the “Help supply services” industry, but how does it contrast to its rivals? We will compare Trueblue to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.

Top Growth Stocks To Invest In Right Now: Buffalo Wild Wings Inc.(BWLD)

Advisors' Opinion:
  • [By Steve Symington]

    That's not to say it was a quiet day for every stock on the market. With earnings season ramping up, brewing giant Anheuser-Busch InBev (NYSE:BUD) and restaurant chain Buffalo Wild Wings (NASDAQ:BWLD) served as an exercise in contrast as investors reacted to their respective quarterly reports.

  • [By Peter Graham]

    A long term performance chart shows Dave & Busters Entertainment�tripling in value�before falling back while�small cap upscale gentlemen's clubs and restaurant owner�RCI Hospitality Holdings, Inc (NASDAQ: RICK) began taking off in 2016 and small cap�Buffalo Wild Wings (NASDAQ: BWLD) is being acquired by Arby��s Restaurant Group:

Top Growth Stocks To Invest In Right Now: Nordstrom Inc.(JWN)

Advisors' Opinion:
  • [By ]

    Cramer and the AAP team say today's weakness is the opportunity they have been patiently waiting for. Their target? Nordstrom (JWN) . Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By JJ Kinahan]

    Retail earnings take center stage the remainder of the week, but aside from that it’s a little hard right now to determine what sort of catalyst is out there that could give the market back some of the “giddy-up” it had last week. Unless the retail earnings really surpass expectations in a big way, it might be difficult to figure out what the next instigator to the upside might be. Thursday looks like a big day, with Walmart Inc. (NYSE: WMT) and J C Penney Company Inc. (NYSE: JCP) scheduled to report before the open and Nordstrom, Inc. (NYSE: JWN) after the close. One question moving into these reports is whether the recent strong retail sales data might have helped the retail sector beyond M.

  • [By Jeremy Bowman]

    A lot has changed since then, however. J.C. Penney badly underperformed its own comparable sales target in the second half of 2016, as comparable sales fell instead of hitting the 3-4% mark the company had projected. Its peers continued to struggle -- Macy's�(NYSE:M),�Kohl's�(NYSE:KSS), and�Nordstrom�(NYSE:JWN) all reported declining comps in the fourth quarter, and Macy's said last year it would close 100 stores.

Wednesday, May 23, 2018

Meridian Wealth Management LLC Has $922,000 Position in Mastercard (MA)

Meridian Wealth Management LLC increased its stake in shares of Mastercard (NYSE:MA) by 70.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,263 shares of the credit services provider’s stock after buying an additional 2,173 shares during the quarter. Meridian Wealth Management LLC’s holdings in Mastercard were worth $922,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Westfield Capital Management Co. LP boosted its holdings in shares of Mastercard by 9.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 647,678 shares of the credit services provider’s stock valued at $91,452,000 after purchasing an additional 56,757 shares in the last quarter. Tredje AP fonden boosted its holdings in shares of Mastercard by 49.4% in the 3rd quarter. Tredje AP fonden now owns 123,057 shares of the credit services provider’s stock valued at $17,376,000 after purchasing an additional 40,662 shares in the last quarter. San Francisco Sentry Investment Group CA boosted its holdings in shares of Mastercard by 4.2% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 12,927 shares of the credit services provider’s stock valued at $1,825,000 after purchasing an additional 522 shares in the last quarter. Pinebridge Investments L.P. boosted its holdings in shares of Mastercard by 291.8% in the 3rd quarter. Pinebridge Investments L.P. now owns 37,374 shares of the credit services provider’s stock valued at $5,278,000 after purchasing an additional 27,834 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of Mastercard by 6.5% in the 3rd quarter. Stifel Financial Corp now owns 686,324 shares of the credit services provider’s stock valued at $96,894,000 after purchasing an additional 42,000 shares in the last quarter. 75.10% of the stock is currently owned by institutional investors and hedge funds.

Get Mastercard alerts:

Mastercard opened at $191.62 on Wednesday, Marketbeat Ratings reports. Mastercard has a 1-year low of $118.97 and a 1-year high of $194.72. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.64 and a quick ratio of 1.64. The stock has a market capitalization of $199.61 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 1.61 and a beta of 1.17.

Mastercard (NYSE:MA) last posted its quarterly earnings data on Wednesday, May 2nd. The credit services provider reported $1.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.25 by $0.25. Mastercard had a return on equity of 91.56% and a net margin of 32.42%. The firm had revenue of $3.58 billion during the quarter, compared to analyst estimates of $3.26 billion. During the same period last year, the company posted $1.01 EPS. The business’s quarterly revenue was up 30.9% on a year-over-year basis. analysts expect that Mastercard will post 6.26 earnings per share for the current year.

MA has been the topic of a number of research analyst reports. Zacks Investment Research raised Mastercard from a “hold” rating to a “buy” rating and set a $188.00 target price on the stock in a report on Wednesday, January 24th. Morgan Stanley raised their price objective on Mastercard from $163.00 to $178.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Oppenheimer raised their price objective on Mastercard from $160.00 to $182.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Barclays raised their price objective on Mastercard from $170.00 to $178.00 and gave the company an “overweight” rating in a report on Tuesday, January 30th. Finally, Sandler O’Neill raised Mastercard from a “sell” rating to a “hold” rating in a report on Thursday, February 1st. Three investment analysts have rated the stock with a hold rating, thirty-two have issued a buy rating and one has given a strong buy rating to the stock. Mastercard presently has a consensus rating of “Buy” and an average price target of $185.95.

In other news, insider Michael Fraccaro sold 3,993 shares of Mastercard stock in a transaction dated Tuesday, April 10th. The stock was sold at an average price of $173.37, for a total value of $692,266.41. Following the completion of the transaction, the insider now directly owns 5,353 shares of the company’s stock, valued at approximately $928,049.61. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Richard Haythornthwaite sold 5,000 shares of Mastercard stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $173.22, for a total value of $866,100.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 306,209 shares of company stock valued at $56,620,393. Corporate insiders own 0.32% of the company’s stock.

Mastercard Profile

Mastercard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. It facilitates the processing of payment transactions, including authorization, clearing, and settlement, as well as delivers related products and services.

Want to see what other hedge funds are holding MA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mastercard (NYSE:MA).

Institutional Ownership by Quarter for Mastercard (NYSE:MA)

Tuesday, May 22, 2018

Wilkins Investment Counsel Inc. Sells 2,883 Shares of 3M (MMM)

Wilkins Investment Counsel Inc. lowered its holdings in shares of 3M (NYSE:MMM) by 6.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,045 shares of the conglomerate’s stock after selling 2,883 shares during the quarter. 3M comprises about 3.1% of Wilkins Investment Counsel Inc.’s investment portfolio, making the stock its 9th biggest position. Wilkins Investment Counsel Inc.’s holdings in 3M were worth $9,888,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Lenox Wealth Advisors Inc. grew its stake in 3M by 16,300.0% in the 4th quarter. Lenox Wealth Advisors Inc. now owns 492 shares of the conglomerate’s stock valued at $116,000 after buying an additional 489 shares during the last quarter. Horan Capital Management acquired a new position in 3M in the 4th quarter valued at $123,000. Virtue Capital Management LLC acquired a new position in 3M in the 4th quarter valued at $127,000. Ballew Advisors Inc acquired a new position in 3M in the 1st quarter valued at $122,000. Finally, Field & Main Bank acquired a new position in 3M in the 4th quarter valued at $140,000. Institutional investors and hedge funds own 65.66% of the company’s stock.

Get 3M alerts:

A number of research analysts recently issued reports on MMM shares. Vetr upgraded shares of 3M from a “buy” rating to a “strong-buy” rating and set a $256.47 target price on the stock in a research note on Friday, March 23rd. Royal Bank of Canada reiterated a “hold” rating and issued a $254.00 target price on shares of 3M in a research note on Thursday, January 25th. Citigroup set a $284.00 target price on shares of 3M and gave the company a “buy” rating in a research note on Saturday, March 24th. JPMorgan Chase lowered their target price on shares of 3M from $227.00 to $221.00 and set an “underweight” rating on the stock in a research note on Thursday, April 26th. Finally, Zacks Investment Research upgraded shares of 3M from a “hold” rating to a “buy” rating and set a $278.00 target price on the stock in a research note on Tuesday, January 23rd. Five analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $241.97.

In other news, EVP Frank R. Jr. Little sold 3,133 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $236.85, for a total transaction of $742,051.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.72% of the stock is currently owned by company insiders.

3M opened at $198.96 on Monday, according to Marketbeat. The company has a current ratio of 1.65, a quick ratio of 1.17 and a debt-to-equity ratio of 1.11. The firm has a market capitalization of $118.12 billion, a price-to-earnings ratio of 21.70, a P/E/G ratio of 1.88 and a beta of 1.17. 3M has a 52-week low of $191.44 and a 52-week high of $259.77.

3M (NYSE:MMM) last posted its quarterly earnings results on Tuesday, April 24th. The conglomerate reported $2.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.50. The company had revenue of $8.28 billion for the quarter, compared to analyst estimates of $8.21 billion. 3M had a net margin of 12.83% and a return on equity of 50.11%. The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the business posted $2.16 EPS. research analysts forecast that 3M will post 10.42 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Shareholders of record on Friday, May 18th will be given a $1.36 dividend. The ex-dividend date is Thursday, May 17th. This represents a $5.44 annualized dividend and a yield of 2.73%. 3M’s dividend payout ratio is 59.32%.

3M Profile

3M Company operates as a diversified technology company worldwide. The company's Industrial segment offers tapes; coated, non-woven, and bonded abrasives; adhesives; ceramics; sealants; specialty materials; purification products; closure systems for personal hygiene products; acoustic systems products; automotive components; and abrasion-resistant films, and paint finishing and detailing products.

Institutional Ownership by Quarter for 3M (NYSE:MMM)

Monday, May 21, 2018

Valeant Pharmaceuticals: Worth At Least $30

When investors look back at the history of Valeant Pharmaceuticals�� (VRX) turnaround, they will remember May 8, 2018. Management��s earnings call for the first quarter is an inflection point for the company as the company builds on revenue growth and higher profits. The company has three catalysts that will lead the stock to a minimum $30 share price. That is, a forward P/E multiple of at least 8 times on sales growth of between 15 �� 20 percent, annually.

Valeant (NYSE:<a href='https://seekingalpha.com/symbol/VRX' title='Valeant Pharmaceuticals International, Inc.'>VRX</a>)

1) Management

Valeant��s new management team is suited to lead the company through the transformation process. It is not run by managers who mislead investors through deceptive earnings numbers during the quarterly conference call. The company has 20,000 dedicated staff that is working hard to reinvigorate drug sales growth. More specifically, the company appointed Mark McKenna from B+L to lead the Salix sales team. I previously noted the need for Salix having strong leadership in this area, and McKenna did not disappoint. The executive restructured the sales team to drive XIFAXAN sales, a drug indication for IBS-D. Before that, Salix suffered from high turnover. Moreover, Salix was not calling on primary care physicians to prescribe the drug to patients. With this new leadership, staff turnover slowed and the sales force successfully boosted XIFAXAN prescriptions up 7 percent year-on-year in the first 13 weeks of 2018.

In the first quarter, Salix grew revenue by 10 percent organically over last year. Bausch + Lomb��s revenue also grew 10 percent. The growth is attributed to strength in the Global Vision Care, International Prescription, and Global Surgical units. As shown in the slide below, Valeant��s top-10 products grew by over 20 percent year-on-year:

Source: Valeant Pharmaceuticals

The revenue potential for the drug does not end there. Salix will invest in studying new indications and new formulations of rifaximin. Further, the company enrolled over 300 patients for a Phase 2 study for treating acute overt hepatic encephalopathy.

2) Product Line-up

Thanks to a rejuvenated sales force, XIFAXAN will continue to drive Salix��s turnaround. Plus, chances are good that Teva Pharmaceuticals (TEVA), through its acquisition of Actavis, will not have an approvable XIFAXAN ANDA. The strong patent protection and intellectual property position ensure Valeant will enjoy profit growth from sales through 2029.

Chart VRX data by YCharts

Above, quarterly earnings report gave both TEVA and VRX stock a lift.

3) New Products

The 44 percent Y/Y growth in prescriptions for Relistor imply meaningful demand ahead for the product. In dermatology, SILIQ is a clear potential for contributing to growth but management is not breaking down sales numbers at the quarterly level. Unfortunately, despite the competitive pricing, SILIQ is likely lagging in sales due to the black box labeling. As a biologic, the drug must be injected (210mg/1.5ml in a single-dose, prefilled syringe). By comparison, patients on Regeneron��s (REGN) Dupixent take an injectable 300mg dose.

Psoriasis suffers are most accustomed to topical ointments. Currently, steroid ointments are taken for no more than two weeks at a time and do not need needles. So, Valeant��s DUOBRII, an ointment-based drug, is another psoriasis drug that could give the company meaningful sales growth. The PDUFA date is coming up next month. BRYHALI, another drug for psoriasis patients, has an October 5 PDUFA date. Both events could give VRX stock a boost. Valeant stock closed at $22.14, a level not seen since the start of the year.

Valuation and Takeaway

While the average price target on Valeant��s stock is $17.12, well below the $22 closing price, value investors should perform their own number crunching in a finbox.io model to arrive at a fair value. Assuming revenue growth picks up in FY 2020 through to FY 2022 in the range of 0 �� 5 percent. Annual revenue would be between $8 billion - $9 billion:

Source: finbox.io (click on the link to enter assumptions)

Assuming a steep discount at between 10 �� 12.5 percent, VRX stock would have a fair value of around $30 a share. Valeant, or (under its new name in July) Bausch Health Companies Inc., clearly has upside higher than that. But just as Teva is deeply undervalued at 7.6 times forward P/E and trading at $21 a share, Valeant��s fair value will rise as the company rolls out new products and continues reporting a strong quarter. Q1 is only a start and investors holding the stock will grow accustomed to strong results ahead. With that, I will raise my $30 price target accordingly.

Please [+]Follow me for value stocks on sale. Click on the big "follow" button beside my avatar.

Coverage on Valeant stock began in 2015 (as a 'sell'). The stock was added as an investment for DIY Value Investing marketplace members.

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in TEVA, VRX, REGN over the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Sunday, May 20, 2018

Facebook Stories Are Demolishing Snapchat

Snapchat might have invented the stories format, but Facebook (NASDAQ:FB) is making the most of it.

The company now known as Snap (NYSE:SNAP) introduced Stories -- slideshows of images and videos that disappear after 24 hours -- way back in 2013. It took Facebook until 2016 to realize it was an actual thing, and it quickly grew multiple products to become larger than Snapchat's Stories.

"Instagram was the first to really take off here," Mark Zuckerberg said on the company's first-quarter earnings call. "Facebook started slower but is now growing quickly too. And WhatsApp Status is by far the biggest of these products and continues to grow quickly."

The company would later reveal that WhatsApp Status has 450 million daily users on the same day Snap reported earnings, no less. Most recently, it told TechCrunch�that Facebook Stories has 150 million daily users.

For reference, Snapchat has 191 million daily users as of the end of the first quarter, it's growing more slowly than all of Facebook's products, and leaked data revealed it had fewer than 150 million daily Stories users as of mid-September last year.

Importantly for investors, Facebook is going to start showing ads in Facebook Stories, something it's already been experimenting with in Instagram Stories since early last year.

Mark Zuckerberg sitting and smiling.

Image source: Facebook.

An opportunity and a challenge

At the beginning of the year, Zuckerberg said he expects Stories to become more popular than feed posts. Chief Product Officer Chris Cox showed some data at Facebook's recent developers conference indicating that Stories is on pace to surpass feed posts sometime next year.

That's both an opportunity and a challenge for Facebook.

The good news is Facebook has quickly become the leader in the stories format. The bad news is it has a huge advertising business selling ads in feeds.

That means Facebook needs to make ads in Stories just as good, if not better, than ads in its feeds. "If we don't do this well, then as more sharing shifts to Stories, that could hurt our business," Zuckerberg told analysts. "But there's upside, real upside here too, if we do a good job."

Indeed, stories ads offer some compelling advantages over ads in news feed or the Instagram feed. Most importantly, they take up the entire screen and command the user's entire focus. But it's still unclear how users will respond to ads in stories and whether Facebook can show as many ads in the format as it does in feeds.

The move comes at a time when Facebook faces pressure on its ad inventory growth. CFO Dave Wehner warned investors of ad load saturation starting in mid-2016, and over the last three quarters, ad impression growth lagged user growth. Opening up ad inventory in stories could offset some of that pressure, which would reduce the need to rely on higher average ad prices to grow ad revenue.

Cutting into Snap's ad sales

Snap has largely disappointed investors with its earnings results since going public, with analysts repeatedly lowering their expectations for revenue growth. Analysts now expect Snap to bring in $1.19 billion in revenue for 2018, which is close to the expectations they had for its 2017 revenue before the company went public a little more than a year ago.

Opening ad inventory in Facebook Stories and continuing to expand ad sales for Instagram Stories could weigh on Snap's revenue growth going forward. Not only do both products offer potentially broader reach than Snapchat's Stories product, but they benefit from Facebook's superior ad targeting data.

Simply put, the return on investment for advertisers is likely better on Facebook's stories products than Snapchat Stories. And with a finite budget with which to experiment with the format, marketers are more likely to buy Facebook's ads because of the better ROI. And those Facebook ad purchases come at the expense of Snap Ads.

What's more, Facebook's just getting started with ads in stories. It hasn't even touched WhatsApp Status, which has three times as many users as Facebook Stories. And it's shown an ability to grow a stories product even while showing ads; it started monetizing Instagram Stories with 150 million users, and it now has 300 million. Less than 10% of Facebook's monthly active users currently view a story on any given day. That's a lot of runway for growth, and a lot of pressure on Snap.

Saturday, May 19, 2018

Zacks: Triple-S Management Co. (GTS) Receives Average Rating of “Hold” from Brokerages

Triple-S Management Co. (NYSE:GTS) has received an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.

Brokers have set a 1-year consensus price objective of $28.00 for the company and are forecasting that the company will post $0.35 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Triple-S Management an industry rank of 74 out of 265 based on the ratings given to its competitors.

Get Triple-S Management alerts:

A number of analysts have weighed in on the company. Zacks Investment Research upgraded Triple-S Management from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research note on Tuesday. ValuEngine upgraded Triple-S Management from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 2nd.

Several institutional investors and hedge funds have recently bought and sold shares of GTS. Teacher Retirement System of Texas bought a new position in shares of Triple-S Management during the 4th quarter worth $202,000. Cambria Investment Management L.P. bought a new position in shares of Triple-S Management during the 1st quarter worth $265,000. MetLife Investment Advisors LLC bought a new position in shares of Triple-S Management during the 4th quarter worth $300,000. AXA bought a new position in shares of Triple-S Management during the 4th quarter worth $301,000. Finally, Alambic Investment Management L.P. bought a new position in shares of Triple-S Management during the 4th quarter worth $321,000. 86.69% of the stock is currently owned by institutional investors and hedge funds.

GTS stock opened at $35.94 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.64 and a current ratio of 0.64. Triple-S Management has a twelve month low of $33.85 and a twelve month high of $34.74. The firm has a market capitalization of $773.83 million, a price-to-earnings ratio of 19.02, a price-to-earnings-growth ratio of 1.75 and a beta of 0.24.

Triple-S Management (NYSE:GTS) last released its earnings results on Tuesday, May 8th. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.36. Triple-S Management had a return on equity of 7.17% and a net margin of 2.13%. The business had revenue of $758.11 million for the quarter, compared to analyst estimates of $734.05 million. During the same quarter last year, the firm posted ($0.18) earnings per share. The business’s revenue was up 4.9% compared to the same quarter last year. sell-side analysts predict that Triple-S Management will post 1.9 earnings per share for the current fiscal year.

Triple-S Management declared that its board has initiated a share repurchase program on Thursday, March 1st that permits the company to buyback $25.00 million in outstanding shares. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s management believes its shares are undervalued.

Triple-S Management Company Profile

Triple-S Management Corporation, through its subsidiaries, provides a portfolio of managed care and related products in the commercial, Medicare, and Medicaid markets in Puerto Rico, the United States. The company operates through three segments: Managed Care, Life Insurance, and Property and Casualty Insurance.

Get a free copy of the Zacks research report on Triple-S Management (GTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com